诚意药业四款产品国家集采中选 股价近期震荡

Group 1 - The core viewpoint of the news is that Chengyi Pharmaceutical successfully participated in the national organized procurement and has four products selected for the procurement period ending December 31, 2028 [1] - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, with Glucosamine Capsules being a key product that accounts for approximately 40% of the first-year demand reported by institutions [1] - The revenue from Glucosamine Capsules reached 345 million yuan in the first three quarters of 2025, surpassing the total revenue of 335 million yuan for the entire year of 2024, with its revenue share increasing from 46.88% to 57.85% [1] Group 2 - The stock price of Chengyi Pharmaceutical has shown a fluctuating trend over the past seven trading days, closing at 11.77 yuan on February 12, 2026, with a single-day decline of 1.18% and a total trading volume of 54.63 million yuan [2] - The stock reached a high of 11.96 yuan and a low of 11.58 yuan during this period, with a cumulative fluctuation of 1.64% over five days [2] - The technical indicators suggest a pressure level at 12.37 yuan and a support level at 11.18 yuan, with recent MACD indicators showing weakness, while KDJ indicators indicate short-term overbought conditions [2]